Benefits of ifosfamide continue to outweigh risks: EMA

In a study funded by the National Institutes of Health (NIH), researchers tested a novel combination treatment approach on mice with tumours with characteristics similar to human astrocytomas — a type of slow-growing glioma—and found tumour regression in 60 percent of the mice treated.

Cyanobacteria are promising but still unexplored natural resources offering a wealth of chemicals for the discovery of pharmaceutical compounds and new drugs.

The US FDA has requested manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately.

A novel tetravalent dengue vaccine candidate developed by Takeda is found demonstrating similar degrees of protection in individuals who had and had not been previously infected with dengue.

Entacapone, the commonly used medication for Parkinson’s disease is not associated with increased risk of prostate cancer, said USFDA, confirming the safety of the drug in a recent announcement. In March 2010, the FDA warned the public about a possible risk of prostate cancer with the entacapone component of the product Stalevo, based on the […]

The European Medicines Agency (EMA) has recommended that the multiple sclerosis medicine fingolimod (Gilenya) must not be used in pregnant women and in women able to have children who are not using effective contraception. If a woman becomes pregnant while using fingolimod, the medicine must be stopped, and the pregnancy will have to be closely […]